RT Journal Article
SR Electronic
T1 COVID-19 severity impacts on long-term neurological manifestation after hospitalisation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.27.20248903
DO 10.1101/2020.12.27.20248903
A1 Andrea Pilotto
A1 Viviana Cristillo
A1 Stefano Cotti Piccinelli
A1 Nicola Zoppi
A1 Giulio Bonzi
A1 Davide Sattin
A1 Silvia Schiavolin
A1 Alberto Raggi
A1 Antonio Canale
A1 Stefano Gipponi
A1 Ilenia Libri
A1 Martina Frigerio
A1 Michela Bezzi
A1 Matilde Leonardi
A1 Alessandro Padovani
YR 2021
UL http://medrxiv.org/content/early/2021/01/02/2020.12.27.20248903.abstract
AB Background Preclinical and clinical investigations have argued for nervous system involvement in SARS-CoV-2 infection and for long term sequalae including neurological manifestationsMethods a sample of 208 previously hospitalized COVID-19 patients, 165 patients were re-assessed at 6 months according to a structured standardized clinical protocol. Premorbid comorbidities and clinical status, severity of COVID-19 disease, complications during and after hospitalization were recorded.Results At 6-month follow-up after hospitalisation due to COVID-19 disease, patients displayed a wide array of neurological symptoms, being fatigue (34%), memory/attention (31%), and sleep disorders (30%) the most frequent. Subjects reporting neurological symptoms were affected by more severe respiratory SARS-CoV-2 infection parameters during hospitalisation. At neurological examination, 37.4% of patients exhibited neurological abnormalities, being cognitive deficits (17.5%), hyposmia (15.7%) and postural tremor (13.8%) the most common. Patients with cognitive deficits at follow-up were comparable for age, sex and pre-admission comorbidities but experienced worse respiratory SARS-CoV-2 infection disease and longer hospitalisation.Conclusions long term neurological manifestations after hospitalization due to COVID-19 infection affects one third of survivors. Multiple neurological abnormalities including mild cognitive impairment are associated with severity of respiratory SARS-CoV-2 infection.Competing Interest StatementAndrea Pilotto served in the advisory board of Z-cube (technology division of Zambon pharmaceuticals); he received honoraria from Z-cube s.r.l., Biomarin, Zambon, Abbvie, Nutricia and Chiesi pharmaceuticals. He received research support from Vitaflo Germany and Zambon Italy. Viviana Cristillo has no financial conflicts to disclose. Stefano Cotti Piccinelli has no financial conflicts to disclose. Nicola Zoppi has no financial conflicts to disclose. Giulio Bonzi has no financial conflicts to disclose. Davide Sattin has no financial conflicts to disclose. Silvia Schiavolin has no financial conflicts to disclose. Alberto Raggi has no financial conflicts to disclose. Antonio Canale has no financial conflicts to disclose. Stefano Gipponi has no financial conflicts to disclose. Ilenia Libri has no financial conflicts to disclose. Martina Frigerio has no financial conflicts to disclose. Michela Bezzi has no financial conflicts to disclose. Matilde Leonardi has no financial conflicts to disclose. Alessandro Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi Pharmaceuticals. He is founded by Grant of Ministry of University (MURST). Funding StatementNo fumino to reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee of ASST Spedali Civili di Brescia Hospital and the requirement for informed consent was waived by the Ethics Commission (NP 4166).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.